Can-Fite BioPharma Ltd. (CANF.TA)
ILA 1.6
(6.67%)
ILA 1.6
(6.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.93 Million USD | -18.05% |
| 2022 | 10.9 Million USD | -20.37% |
| 2021 | 13.69 Million USD | -8.1% |
| 2020 | 14.9 Million USD | 6.15% |
| 2019 | 14.03 Million USD | 52.04% |
| 2018 | 9.23 Million USD | 12.33% |
| 2017 | 8.22 Million USD | -6.62% |
| 2016 | 8.8 Million USD | 33.8% |
| 2015 | 6.57 Million USD | -7.75% |
| 2014 | 7.13 Million USD | -20.67% |
| 2013 | 8.99 Million ILS | 49.74% |
| 2012 | 6 Million USD | 13.98% |
| 2011 | 5.26 Million USD | 16.83% |
| 2010 | 4.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 1.98 Million USD | -3.49% |
| 2023 FY | 8.93 Million USD | -18.05% |
| 2023 Q2 | 1.98 Million USD | -31.91% |
| 2023 Q1 | 2.9 Million USD | -11.34% |
| 2023 Q3 | 2.06 Million USD | 4.09% |
| 2022 Q1 | 2.57 Million USD | -39.15% |
| 2022 FY | 10.9 Million USD | -20.37% |
| 2022 Q2 | 2.27 Million USD | -11.69% |
| 2022 Q3 | 2.77 Million USD | 22.12% |
| 2022 Q4 | 3.28 Million USD | 18.11% |
| 2021 FY | 13.69 Million USD | -8.1% |
| 2021 Q2 | 3.38 Million USD | 45.88% |
| 2021 Q1 | 2.31 Million USD | -37.38% |
| 2021 Q3 | 3.76 Million USD | 11.17% |
| 2021 Q4 | 4.23 Million USD | 12.52% |
| 2020 Q2 | 4.03 Million USD | -9.81% |
| 2020 FY | 14.9 Million USD | 6.15% |
| 2020 Q1 | 4.47 Million USD | -6.77% |
| 2020 Q4 | 3.7 Million USD | 37.66% |
| 2020 Q3 | 2.69 Million USD | -33.33% |
| 2019 FY | 14.03 Million USD | 52.04% |
| 2019 Q2 | 3.28 Million USD | 63.33% |
| 2019 Q3 | 3.94 Million USD | 20.1% |
| 2019 Q4 | 4.79 Million USD | 21.71% |
| 2019 Q1 | 2.01 Million USD | -28.01% |
| 2018 FY | 9.23 Million USD | 12.33% |
| 2018 Q4 | 2.79 Million USD | 40.65% |
| 2018 Q3 | 1.98 Million USD | -11.27% |
| 2018 Q2 | 2.23 Million USD | 0.77% |
| 2018 Q1 | 2.22 Million USD | -11.32% |
| 2017 Q1 | 2.01 Million USD | -22.16% |
| 2017 FY | 8.22 Million USD | -6.62% |
| 2017 Q4 | 2.5 Million USD | 42.66% |
| 2017 Q3 | 1.75 Million USD | -9.85% |
| 2017 Q2 | 1.94 Million USD | -3.46% |
| 2016 Q3 | 2.33 Million USD | 7.13% |
| 2016 Q1 | 1.7 Million USD | -29.38% |
| 2016 Q2 | 2.17 Million USD | 27.78% |
| 2016 Q4 | 2.59 Million USD | 11.05% |
| 2016 FY | 8.8 Million USD | 33.8% |
| 2015 Q4 | 2.41 Million USD | 71.11% |
| 2015 Q1 | 1.21 Million USD | -26.85% |
| 2015 Q2 | 1.54 Million USD | 27.09% |
| 2015 Q3 | 1.41 Million USD | -8.62% |
| 2015 FY | 6.57 Million USD | -7.75% |
| 2014 Q2 | 2.16 Million USD | 11.9% |
| 2014 Q3 | 1.37 Million USD | -36.36% |
| 2014 FY | 7.13 Million USD | -20.67% |
| 2014 Q4 | 1.65 Million USD | 20.56% |
| 2014 Q1 | 1.93 Million USD | -43.88% |
| 2013 FY | 8.99 Million ILS | 49.74% |
| 2013 Q1 | 1.72 Million USD | -17.5% |
| 2013 Q4 | 3.44 Million USD | 122.01% |
| 2013 Q2 | 2.18 Million USD | 26.66% |
| 2013 Q3 | 1.55 Million USD | -28.89% |
| 2012 FY | 6 Million USD | 13.98% |
| 2012 Q4 | 2.08 Million USD | 73.79% |
| 2012 Q2 | 1.24 Million USD | -21.33% |
| 2012 Q1 | 1.57 Million USD | 22.02% |
| 2012 Q3 | 1.2 Million USD | -3.25% |
| 2011 Q1 | 1.63 Million USD | 28.59% |
| 2011 FY | 5.26 Million USD | 16.83% |
| 2011 Q2 | 1.39 Million USD | -14.91% |
| 2011 Q3 | 1.16 Million USD | -16.14% |
| 2011 Q4 | 1.29 Million USD | 10.73% |
| 2010 Q3 | 1 Million USD | 0.0% |
| 2010 FY | 4.5 Million USD | 0.0% |
| 2010 Q4 | 1.27 Million USD | 27.07% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Matricelf Ltd | 11.78 Million ILA | 24.158% |